Clinical trial NCT04179669: Safety and Efficacy of IBI306 in HeFH Patients
Official title: A Study to Evaluate Safety and Efficacy of IBI306 in Patients With Heterozygous Familial Hypercholesterolemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Heterozygous Familial Hypercholesterolemia
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Sponsor class: INDUSTRY
First posted: 2019-11-27
Enrollment: 149
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and low-density lipoprotein cholesterol (LDL-C) uptake. In the phase I study, IBI306 was shown to be safe and well tolerated. There was robust reduction in LDL-C, Apo(B), non-HDL-C and lipoprotein (a) in healthy subjects. This study is a randomized, double-blind, placebo-controlled, repeated-dosing, multiple ascending dose trial to evaluate the efficacy and safety of a novel PCSK-9 anti-body, IBI306, in Chinese patients with heterozygous familial hypercholesterolemia.

Detailed description: The study plans to enroll 148 patients with heterozygous familial hypercholesterolemia. Subjects will maintain a low-fat diet and stable current lipid-lowering therapy for at least 4 weeks and will be randomized into different dose groups at a 1:1 ratio, followed by a 2:1 randomization double-blind treatment with subcutaneous IBI306 150 mg (n=49) or placebo (n=25) every two weeks; or subcutaneous injection of IBI306 450mg (n=49) or placebo (n=25) every four weeks. Treatment lasts for 12 weeks. After 12 weeks, each group enters a 12-week open-label treatment, in which IBI306 subjects continue to receive IBI306, and placebo subjects shift to receive IBI306. The primary endpoint is the percent change in LDL-C levels relative to baseline at 12 weeks. Secondary endpoints include changes in baseline lipid levels, drug safety, and immunogenicity at 12 weeks and 24 weeks. The exploratory endpoint is the population pharmacokinetic profile of IBI306 in Chinese subjects with heterozygous familial hypercholesterolemia. If necessary, the dose of IBI306 will be adjusted accordingly based on the results of the ongoing multi-dose escalation study. After the open period, the subjects will be given a safety visit for 8 weeks.

Eligibility criteria: Inclusion Criteria:

• Subjects must meet all of the following inclusion criteria in order to be included in the study:

* Provide a signed and dated informed consent form
* Men or women 18 to 70 years of age at screening
* Weight ≥ 40 kg during screening
* Confirmed diagnosis of heterozygous familial hypercholesterolemia
* Maintain a low-fat diet and stabilize the current lipid-lowering therapy

Exclusion Criteria:

• Subjects who do not meet any of the following exclusion criteria cannot be included in the study:

* Patients diagnosed as homozygous familial hypercholesterolemia
* Dialysis or plasmapheresis performed within 4 months prior to screening
* History of liver transplant
* Subjects adjusted for treatment of statins, ezetimibe, niacin, omega-fatty acids within 4 weeks prior to screening
* New York Heart Association (NYHA) grade III or IV heart failure, or recent detection of left ventricular ejection fraction ≤ 30%
* Have serious cardiovascular, cerebrovascular, liver and kidney related diseases

Primary outcomes:
measure: Percentage of LDL-C decreased from baseline injection.
timeFrame: at 12 weeks
Secondary outcomes:
measure: Percentage change of LDL-C from baseline
timeFrame: to 24 weeks
measure: Changes in LDL-C levels relative to baselin
timeFrame: at 12 and 24 weeks
measure: The proportion of patients with LDL-C that were 50% lower than baseline
timeFrame: by 12 weeks and 24 weeks
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Anzhen Hospital, Capital Medical University
Study officials:
References: